90% of drug candidates selected in the preclinical phases fail in the clinical assays on Man, mainly for efficacy or safety issues which have not been previously detected. This has a huge economic impact on the pharmaceutical / biotech companies but also on patients, who are waiting for the innovative treatments they need.
This huge attrition rate indicates a lack of efficient tools at the early stages of development to evaluate correctly their new molecules, when researchers and developers must take strategic “go / no go” decisions about their projects.
To help researchers to evaluate better their news drugs at early stages of development, Nanobiose created SecretCells®, a micro-fluidic lab-on-a-chip for a better in vitro safety / efficacy evaluation. In SecretCells®, the evaluation is based on both a profiling of secreted biomarkers of interest and a cytotoxicity assay. SecretCells® combines in the same device both infused 2D / 3D cell culture capacities, to better mimic in-vivo like conditions, with the real-time capture on a removable biosensor of secreted biomarkers (up to 9 simultaneously) which are revealed with a reagent kit. SecretCells® just requires classical equipments like incubators, peristaltic pumps or syringe pumps and a fluorescence microscope or a slide scanner for the fluorescent readouts.
Nanobiose is a specialized company founded in july 2016 near Chambéry (France), at the alpine crossroads of Europe. Nanobiose is developing innovative lab-on-a-chip solutions for improved in vitro evaluation of the activity/safety of new molecular entities at an early stage of development ranging from: